Global Virus Network (GVN) Convenes Discussions with International Top Experts to Combat Growing Novel Coronavirus Epidemic

The GVN Is Bridging Gaps in the Global Emergency Response and Serving as a “Go-To” Resource for Members Needing Assistance in Obtaining and Disseminating Cutting-Edge Scientific Research

Baltimore, Maryland, USA, February 6, 2020:  The Global Virus Network (GVN), representing 53 Centers of Excellence and 9 Affiliates in 32 countries comprising foremost experts in every class of virus causing disease in humans and some animals, is holding regular strategic discussions with its members regarding the growing novel coronavirus, known as 2019-nCoV, which originated in Wuhan, China this past December.  The GVN has identified areas to support its Centers and work with international organizations addressing the growing epidemic.

“GVN Centers of Excellence and Affiliates, with strong working relationships among them, are poised to engage in any outbreak situation by providing the world’s only network of top basic virologists from around the globe covering all classes of human viral threats,” said Christian Bréchot, MD, PhD, President of the GVN, and a Professor at the University of South Florida.  “Many members of the GVN are initiating various projects regarding diagnostics, vaccines and therapeutics to combat this rapidly expanding, novel, outbreak.  However, there are still resource needs and information gaps that need to be filled, and GVN is helping to serve as that important resource. In particular, we have engaged GVN Africa to foster collaborations on diagnostics and other important resource needs.”

“We are organizing a workshop for the diagnosis of 2019-nCoV in Dakar for 15 countries in a joint partnership with Africa Centres for Disease Control and Prevention (Africa CDC) in collaboration with the World Health Regional Office for Africa and the West African Health Organization before the epidemic arrives,” said Amadou Alpha Sall, PhD, General Administrator, Institut Pasteur in Dakar, the region’s top biomedical research facility, and Member, Global Virus Network (GVN).  “We are contributing to build ‘the Africa We Want’ in 2063 Africa agenda, while making sure that we anticipate the threat rather than reacting to it.  This is a new model of work for Africa under the leadership of Africa CDC catalyzed by Ebola and other outbreaks that may change the public health practice in Africa in the coming years.”

2019-nCoV has spread to other global regions, including Hong Kong, Macao, Taiwan, Australia, Belgium, Cambodia, Canada, Finland, France, Germany, India, Italy, Japan, Malaysia, Nepal, Philippines, Russia, Sri Lanka, Singapore, South Korea, Spain, Sweden, Thailand, The Republic of Korea, United Arab Emirates, United Kingdom, United States and Vietnam.  As of Thursday morning, February 6, there are over 28,000 infected and more than 560 dead, while the rest of the world reports more than 260 confirmed cases and two deaths outside of mainland China.  The numbers are likely higher.

On January 29, The Peter Doherty Institute for Infection and Immunity (Doherty Institute), a GVN Center of Excellence, in Melbourne announced that, for the first time outside of China, they successfully grew 2019-nCoV from a patient sample in the laboratory and were the first to share the virus with public health laboratories globally and the World Health Organization (WHO). This provides those laboratories, including those within the GVN, with crucial information to help combat the virus.

Mike Catton, MB BS, FRCPA, Deputy Director of the Doherty Institute and Member of the GVN, said that possession of a virus isolate extended what could be achieved with molecular technology in the fight against this virus.

The Doherty Institute-grown virus is expected to be used to generate an antibody test, among other uses, which allows detection of the virus in patients who haven’t displayed symptoms and were therefore unaware they had the virus.

“An antibody test will enable us to retrospectively test suspected patients so we can gather a more accurate picture of how widespread the virus is, and consequently, among other things, the true mortality rate,” said Dr. Catton.

On January 23, after Chinese researchers published the sequence of 2019-nCoV, a GVN partner, the Coalition for Epidemic Preparedness Innovations (CEPI), announced that it will fund three vaccine initiatives with $12.5 million, including GVN Center of Excellence, the Australian Infectious Diseases Research Centere at the University of Queensland (UQ). Further, on February 3, CEPI and GSK announced that GSK will make its established pandemic vaccine adjuvant platform technology available to enhance the development of an effective vaccine against 2019-nCoV. Adjuvants are added to a vaccine to boost the immune response to produce more antibodies and longer-lasting immunity, thus minimizing the dose of antigen needed.

“The University of Queensland’s ‘molecular clamp technology’ provides stability to the viral protein that is the primary target for our immune defense,” said Paul Young, PhD, Head of the School of Chemistry and Molecular Biosciences at UQ, Australia and Member of the GVN.  “The technology has been designed as a platform approach to generate vaccines against a range of human and animal viruses and has shown promising results in the laboratory targeting viruses such as influenza, Ebola, Nipah and MERS coronavirus. The availability of the GSK adjuvant will enable us to carry out important pre-clinical experiments designed to assess vaccine effectiveness.”

Other GVN researchers are sourcing their MERS and SARS coronavirus expertise to advance vaccine development for this new outbreak. “With our experience and novel contributions to the MERS and SARS outbreaks as well as the deadly zoonosis influenza viruses, H7N7 and H5N1, we are working to develop a vaccine against this new, novel coronavirus,” said Ab Osterhaus, PhD, DVM, Director of the The Research Center for Emerging Infections and Zoonosis (RIZ) at the University of Veterinary Medicine in Hannover, Germany, a Center Director of the GVN, and CEO of Artemis One Health Foundation, Germany. “Specifically, we are poised to study T-Cell and IgM antibody response using our expertise in animal models.”

Linfa Wang, PhD, Director of the Programme in Emerging Infectious Diseases at Duke-NUS Medical School and a Center Director of the GVN, Singapore, is developing diagnostics for 2019-nCoV with collaborators in China. Dr.  Wang, who sequenced and named Australia’s bat-borne Hendra virus more than 25 years ago, has obtained multiple isolates of the virus, and is focused on studying serology and cross-reactivity and contamination on diagnostics. Dr. Wang believes the deadly new coronavirus “appears to be more infectious than the 2003 SARS coronavirus.”  Further he warns, “Despite the possibility for criticisms of an overreaction, it is imperative that we act quickly and effectively, as the alternative of an underreaction could potentially lead to more deaths worldwide.”

“We are funneling resources towards this new novel virus research on animal infection, transmission and reservoirs,” said Joaquim Segalés, DVM, PhD, Researcher from the Centre de Recerca en Sanitat Animal (CReSA), Spain and a Center Director of the GVN.  “We also have a number of reagents against MERS available, and are waiting to receive isolates of the virus, hopefully from our GVN colleagues.”

“Our GVN colleagues in Melbourne at the Doherty Institute are shipping a sample of this new novel virus as we speak,” said Johan Neyts, PhD, Professor of Virology, Rega Institute for Medical Research at the University of Leuven and a Center Director of the GVN.  “We are developing a dual yellow fever/2019-nCoV using our revolutionary Plasmid Launched Live Attenuated Virus (PLAV) technology based. We managed recently to do the same with yellow fever and other viruses such as Lassa and rabies.  Further, using our fully automated high biosafety laboratory, we are leading an intensive research effort to develop therapeutics against 2019-nCoV.”

“The GVN wishes to help and collaborate with other scientists globally, and especially to include the China GVN and China CDC, whose scientists, under the leadership of Dr. George F. Gao, have made important initial contributions to the genomic characterization and epidemiology of this deadly virus,” said Robert Gallo, MD, Co-Founder and Chairman of the International Scientific Leadership Board of the GVN.  Dr. Gallo is also The Homer & Martha Gudelsky Distinguished Professor in Medicine and Director, Institute of Human Virology (IHV) at the University of Maryland School of Medicine, a GVN Center of Excellence.

About the Global Virus Network (GVN)
The Global Virus Network (GVN) is essential and critical in the preparedness, defense and first research response to emerging, exiting and unidentified viruses that pose a clear and present threat to public health, working in close coordination with established national and international institutions.  It is a coalition comprised of eminent human and animal virologists from 53 Centers of Excellence and 9 Affiliates in 32 countries worldwide, working collaboratively to train the next generation, advance knowledge about how to identify and diagnose pandemic viruses, mitigate and control how such viruses spread and make us sick, as well as develop drugs, vaccines and treatments to combat them.  No single institution in the world has expertise in all viral areas other than the GVN, which brings together the finest medical virologists to leverage their individual expertise and coalesce global teams of specialists on the scientific challenges, issues and problems posed by pandemic viruses. The GVN is a non-profit 501(c)(3) organization. For more information, please visit www.gvn.org. Follow us on Twitter @GlobalVirusNews

Media Contact:
Nora Samaranayake, GVN
410-706-8614
nsamaranayake@gvn.org

Global Virus Network (GVN) Experts Combat New Worldwide Coronavirus Outbreak

GVN stands by China and relevant international organizations to support efforts to mitigate the new strain of coronavirus, named 2019-nCoV

Baltimore, Maryland, USA, January 30, 2020: As airlines suspend flights, countries evacuate citizens from China and nearly 60 million Chinese experience a lockdown, the Global Virus Network (GVN), representing 53 Centers of Excellence and 9 Affiliates in 32 countries comprising foremost experts in every class of virus causing disease in humans and some animals, will stand by China and relevant international organizations to support efforts to mitigate the new strain of coronavirus, named 2019-nCoV, originating from Wuhan, China. The outbreak, which causes respiratory illness, originated in a seafood and meat market in Wuhan, a city of 11 million, and likely jumped to humans from bats. 2019-nCoV has spread to other global regions, including Hong Kong, Macau, Taiwan, Australia, Cambodia, Canada, Finland, France, Germany, India, Japan, Malaysia, Nepal, Philippines, Sri Lanka, Singapore, Thailand, The Republic of Korea, United Arab Emirates, United States and Vietnam. As of Thursday, January 30, 6:00 AM ET according to Chinese authorities there are nearly 8,000 infected and 170 dead, while the rest of the world reports more than 110 confirmed cases outside of China.

“Many members of the GVN are initiating various projects regarding diagnostics, vaccine and therapeutics to combat this rapidly expanding, novel, outbreak,” said Christian Bréchot, MD, PhD, President of the GVN, and a Professor at the University of South Florida. “We support current organizations such as the World Health Organization and stand ready to serve as global first-responders to this dangerous virus and operate as an international clearinghouse to educate, inform and disseminate critical information to governments, health organizations, healthcare practitioners and the public-at-large.”

On January 23, after Chinese researchers published the sequence of 2019-nCoV, a GVN partner, the Coalition for Epidemic Preparedness Innovations (CEPI), announced that it will fund three vaccine initiatives with $12.5 million. One of those recipients includes GVN Center of Excellence, the Australian Infectious Diseases Research Centere at the University of Queensland (UQ).

“The University of Queensland’s molecular clamp technology provides stability to the viral protein that is the primary target for our immune defense,” said Keith Chappell, PhD, Senior Research Fellow in the School of Chemistry and Molecular Biosciences at UQ, Australia. “The technology has been designed as a platform approach to generate vaccines against a range of human and animal viruses and has shown promising results in the laboratory targeting viruses such as influenza, Ebola, Nipah and MERS coronavirus.”

Other GVN researchers are sourcing their MERS and SARS coronavirus expertise to advance vaccine development for this new outbreak. “With our experience and novel contributions to the MERS and SARS outbreaks as well as the deadly zoonosis influenza viruses, H7N7 and H5N1, we are working to develop a vaccine against this new, novel coronavirus,” said Ab Osterhaus, PhD, DVM, Director, The Research Center for Emerging Infections and Zoonosis (RIZ), University of Veterinary Medicine in Hannover, Germany, Center Director, Global Virus Network (GVN) CEO, Artemis One Health Foundation, Germany.

Linfa Wang, PhD, Director, Programme in Emerging Infectious Diseases at Duke-NUS Medical School, Center Director, Global Virus Network (GVN), Singapore, is developing diagnostics for 2019-nCoV with collaborators in China. Dr. Wang, who sequenced and named Australia’s bat-borne Hendra virus more than 25 years ago, believes the deadly new coronavirus “appears to be more infectious than the 2003 SARS coronavirus.” Further he warns, “Despite the possibility for criticisms of an overreaction, it is imperative that we act quickly and effectively, as the alternative of an underreaction could potentially lead to more deaths worldwide.”

“The use of human ACE2 2019-nCoV is now confirmed by multiple actual viral isolates from the laboratory of Zhengli Shi, PhD, who is the director of center for infectious disease at Wuhan Institute of Virology, Chinese Academy of Sciences, and who was responsible for identifying many of the bat SARS-like CoV in the past ten years,” said Benhur Lee, MD, Professor of Microbiology, Member, Global Virus Network (GVN), Icahn School of Medicine at Mount Sinai, USA. “I believe that all symptomatic people with or without cough is potentially contagious with this new novel virus as Shi’s research shows virus-specific IgM being detected in patients one week post-symptoms onset; the finding that most patients have neutralizing IgG+ antibodies by two weeks post-symptoms; patients as having cough/chest congestion with high virial loads; and, one 2019-nCoV virus positive patient as having fever as the only symptom.”

About the Global Virus Network (GVN)
The Global Virus Network (GVN) is essential and critical in the preparedness, defense and first research response to emerging, exiting and unidentified viruses that pose a clear and present threat to public health, working in close coordination with established national and international institutions.  It is a coalition comprised of eminent human and animal virologists from 53 Centers of Excellence and 9 Affiliates in 32 countries worldwide, working collaboratively to train the next generation, advance knowledge about how to identify and diagnose pandemic viruses, mitigate and control how such viruses spread and make us sick, as well as develop drugs, vaccines and treatments to combat them.  No single institution in the world has expertise in all viral areas other than the GVN, which brings together the finest medical virologists to leverage their individual expertise and coalesce global teams of specialists on the scientific challenges, issues and problems posed by pandemic viruses. The GVN is a non-profit 501(c)(3) organization. For more information, please visit www.gvn.org. Follow us on Twitter @GlobalVirusNews

Media Contact:
Nora Samaranayake, GVN
410-706-8614
nsamaranayake@gvn.org

Six Internationally Renowned Virus Research Institutions Join the Global Virus Network to Combat Viral Diseases

GVN Adds Four Centers of Excellence and Two Affiliates from India, Peru, Republic of Uzbekistan, South Korea, United States and Zimbabwe

Baltimore, Maryland, USA, October 24, 2019: The Global Virus Network (GVN), representing 52 Centers of Excellence and 9 Affiliates in 32 countries comprising foremost experts in every class of virus causing disease in humans and animals, announced today the addition of four new Centers of Excellence including, Manipal Academy of Higher Education (An Institution of eminence deemed to be University), The Tropical Medicine Institute “Alexander von Humboldt” of the Universidad Peruana Cayetano Heredia, the Korea National Institute of Health’s Center for Infectious Diseases Research, the Wyss Institute for Biologically Inspired Engineering at Harvard University, and two Affiliates, the Research Institute of Virology Ministry of Health of the Republic of Uzbekistan and the Antiviral Pharmacology Laboratory and Clinical Trials Research Center Virology Program at the University of Zimbabwe. The announcement was made by Christian Bréchot, MD, PhD, President of the GVN and Robert Gallo, MD, Co-Founder and Chairman of the International Scientific Leadership Board of the GVN.

“The GVN continues to serve as a catalyst uniquely connecting top virus research institutions from around the world to build collaborative, effective alliances and eradicate viral threats. In fact, these six Centers and Affiliates perfectly illustrate this concept, combining Centers with highly complementary skills, from all over the world,” said Bréchot, who is also Professor at the University of South Florida. “We support current organizations such as the World Health Organization and stand ready to serve as global first-responders to dangerous viruses and operate as an international clearinghouse to educate, inform and disseminate critical information to governments, health organizations, healthcare practitioners and the public-at-large.”

“Since HIV/AIDS first appeared, I strongly have believed mankind will best be served if the world’s leading virologists are organized and better equipped to deal with existing and new viral threats,” said Gallo, who is also The Homer & Martha Gudelsky Distinguished Professor in Medicine and Director, Institute of Human Virology (IHV) at the University of Maryland School of Medicine, a GVN Center of Excellence. “These diverse new members of the GVN add depth of expertise and global reach to our network. They will help us better combat viral threats and train the next generation of virologists.”

The Manipal Institute of Virology (MIV) GVN Center of Excellence is led by Arunkumar Govindakarnavar, PhD, MSc, BSc, Professor and Director, MIV, Manipal Academy of Higher Education (MAHE). MIV is a regional center for diagnostic virology and research, and the regional reference laboratory for Influenza viruses and an Indian Council of Medical Research (ICMR) Grade I Virus Research and Diagnostic Laboratory (VRDL) supported by the Department of Health Research (DHR), National Vector Borne Disease Control Programme (NVBDCP) Apex referral laboratory for arboviruses, Ministry of Health and Family Welfare (MOHFW) and Government of India (GOI). Apart from disease diagnostics, MIV supports the state and national health services for outbreak investigations. MIV has established 33 surveillance centers in hospitals across 16 districts of 10 states capable of detecting and responding to viruses and bacteria.

“MIV was instrumental in confirming more than 150 viral outbreaks, and closely involved in outbreaks including the Nipah virus, Zika virus, Acute Encephalitis Syndrome, Hepatitis A virus and Kyasanur Forest Disease,” said Arunkumar. “We look forward to sharing our experiences with the GVN and launching new collaborations to advance the field in our area of expertise in virology.”

The Tropical Medicine Institute “Alexander von Humboldt” of the Universidad Peruana Cayetano Heredia GVN Center of Excellence is led by Eduardo Gotuzzo, MD, FACP, FIDSA, FESCMID, Emeritus Professor, Universidad Peruana Cayetano Heredia. The Institute is multidisciplinary, specializing in infectious and tropical diseases, with global leadership that conducts research, innovates and diversifies, and promotes public policies and technology transfer contributing to Peru’s development. The Institute specializes in HTLV and its clinical complications, HIV/AIDS and antiretroviral drug therapy, human rhinovirus, hepatitis B and some C viruses, and arboviruses such as Zika virus.

“We have a large HTLV patient cohort and are the country’s most experienced in treating patients with HIV/AIDS, which unfortunately continues to grow due to the significant migration of people from Venezuela,” said Gotuzzo. “The GVN will provide a unique opportunity to advance our studies and international collaborations as well as unique training opportunities.”

The Korea National Institute of Health’s Center for Infectious Diseases Research GVN Center of Excellence is led by Youngmee Jee MD, PhD, Director, Center for Infectious Diseases Research (CID), Korea National Institute of Health (KNIH). KNIH is the only national public health research institution to produce scientific evidence to shape public health policies. The CID, one of three research centers at KNIH, is responsible for research on infectious diseases caused by viral and bacterial pathogens with four primary goals: (1) to enhance the national capacity responding to infectious disease threats, (2) to efficiently control emerging and acute/chronic infectious diseases, (3) to explore infectious diseases affecting human health in relation to climate change, (4) to establish national and international networks through collaborative studies on infectious diseases, and (5) to collect and manage human pathogen resources in Korea.

“I participated in the GVN’s international meeting last June in Barcelona and found the sessions and shared expertise very valuable,” said Jee. “Our broad experience with various global research intuitions such as the World Health Organization and fellow Korean GVN Center of Excellence, the International Vaccine Institute, will deepen GVN’s expertise and advance basic and applied research on emerging viruses and acute and chronic viruses through new collaborations with GVN members.”

The Wyss Institute for Biologically Inspired Engineering at Harvard University GVN Center of Excellence is led by Founding Director Donald Ingber, MD, PhD, who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School, Senior Associate in the Vascular Biology Program at Boston Children’s Hospital and Professor of Bioengineering at Harvard’s John A. Paulson School of Engineering and Applied Sciences. The Wyss Institute leverages recent insights into how nature builds, controls and manufactures to develop new engineering innovations – a new field of research the Institute refers to as Biologically Inspired Engineering. By emulating biological principles of self-assembly, organization and regulation, the Institute is developing disruptive technology solutions for healthcare, energy, architecture, robotics and manufacturing, which are translated into commercial products and therapies through the formation of new startups and corporate alliances. The Institute’s unique Organ-on-a-Chip (Organ Chip) technology enables modeling of human tissues with in vivo-like architectures and physiologies to study viral infection, propagation, evolution, patient-to-patient transmission and host responses in vitro. Wyss Institute researchers are leveraging human Organ Chips and a variety of its other core technologies in a highly multi-disciplinary approach to create rapid, sensitive, and highly specific diagnostics for detection of viruses, broad spectrum anti-virus vaccines, new antiviral therapeutics, novel drug- and gene-delivering viral vectors, and, culture-free viral infectivity assays.

“We offer the GVN a truly unique skill set in bioengineering and technology innovation that will nicely complement the more classic virology focus of most other members of the network, as well as numerous powerful enabling technologies that GVN members should find extremely useful,” said Ingber. “We look forward to the GVN helping us to identify relevant funding opportunities and sources of clinical samples, and to team with us to build stronger consortia around specific problems, and if possible, to provide support for fellows and trainees.”

The Research Institute of Virology Ministry of Health of the Republic of Uzbekistan, which is led by Musabaev Erkin Isakovich, PhD, Professor, Research Institute of Virology of the Ministry of Health of the Republic of Uzbekistan, is an Affiliate through GVN Centers of Excellence, Istituto Nazionale Tumori “Fondazione Pascale” National Cancer Institute, Russian Smorodintsev Research Institute of Influenza (SRII) and Institute of Human Virology at the University of Maryland School of Medicine. The Institute comprises a laboratory of new and re-emerging viral infections (in the structure of National Influenza Center), a reference laboratory, scientific departments, department of molecular-genetic analysis and cultural research, an international department, in-patient department (hospital), including 200 beds to treat infectious disease patients, laboratory-diagnostic and auxiliary departments and rooms and an ambulatory-out-patient diagnostical hepatology center. The Institute’s expertise includes viral hepatitis, liver cirrhosis with viral etiology, HIV/AIDS, new and re-emerging infections, influenza, and intestinal infections.

“We are pleased to join with three renowned GVN Centers of Excellence to become an Affiliate member of the GVN,” said Isakovich. “The GVN will provide opportunities in information sharing and collaborations on research, grants, projects and training initiatives, particularly in the area of scientific exchanges between fellows.”

The Antiviral Pharmacology Laboratory and Clinical Trials Research Center Virology Program at the University of Zimbabwe (UZ), which is led by Charles Chiedza Maponga, PharmD, MHPE, Director, GVN Affiliate at UZ and Justen Manasa, PhD, Co-Director, Virology, Genetics, is an Affiliate through GVN Center of Excellence, University at Buffalo HIV and HCV Clinical Pharmacology Laboratory. UZ is home to a National Institutes of Health (NIH) AIDS Clinical Trials Unit that conducts research with National Institute of Allergy and Infectious Diseases (NIAID) HIV Research networks including the AIDS Clinical Trials Group (ACTG), International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) and Microbial Trials Network (MTN). In addition, UZ has a NIAID HIV Clinical Pharmacology Specialty Laboratory. Research priorities include HIV, HCV, HPV and other global virus research agendas. The Antiviral Pharmacology Laboratory is home to a Fogarty-supported HIV Clinical Pharmacology Research Program that is conducted in collaboration with the University at Buffalo. As the HIV/AIDS epidemic has continued to impact developing countries, the need for training in HIV/AIDS Clinical Pharmacology has also expanded in scope, including in clinical expertise such as cancer, behavioral sciences, Alzheimer’s disease, nanomedicine and pediatrics.

“We have a productive collaboration with the GVN Center of Excellence University of Buffalo HIV and HCV Clinical Pharmacology Laboratory and are thrilled to grow our relationship into the GVN as an Affiliate,” said Maponga and Manasa. “Not only do we have a regional capacity to substantively contribute to global research through the GVN, but we welcome training exchange programs that expand our breadth of expertise.”

About the Global Virus Network (GVN)

The Global Virus Network (GVN) is essential and critical in the preparedness, defense and first research response to emerging, exiting and unidentified viruses that pose a clear and present threat to public health, working in close coordination with established national and international institutions.  It is a coalition comprised of eminent human and animal virologists from 52 Centers of Excellence and 9 Affiliates in 32 countries worldwide, working collaboratively to train the next generation, advance knowledge about how to identify and diagnose pandemic viruses, mitigate and control how such viruses spread and make us sick, as well as develop drugs, vaccines and treatments to combat them.  No single institution in the world has expertise in all viral areas other than the GVN, which brings together the finest medical virologists to leverage their individual expertise and coalesce global teams of specialists on the scientific challenges, issues and problems posed by pandemic viruses. The GVN is a non-profit 501(c)(3) organization. For more information, please visit www.gvn.org. Follow us on Twitter @GlobalVirusNews

Media Contact:

Nora Samaranayake, GVN
410-706-8614
nsamaranayake@gvn.org

GLOBAL VIRUS NETWORK HOSTS SIXTH SHORT COURSE

Top GVN Experts Inspire Rising International Virologists

Baltimore, Maryland, USA, August 29, 2019: The Global Virus Network (GVN) earlier this month held its 6th Annual Short Course in Basic and Translational Virology on July 28-August 3 for 18 early-career human and animal virologists from Argentina, Bolivia, Germany, Hong Kong, Jamaica, Japan, Kenya, Nigeria, South Korea and United States of America. The preeminent one-week course on basic, translational and clinical aspects of viruses featured world-renowned researchers drawn from GVN Centers of Excellence, encompassing 51 Centers of Excellence and nine affiliates in 30 countries and comprising foremost experts in every class of virus causing disease in humans and some animals. The Short Course is designed to counter a declining number of researchers entering the field of human and animal virology.

The announcement was made by Robert Gallo, MD, Co-Founder and International Scientific Advisor, GVN and Christian Bréchot, MD, PhD, President, GVN.

“The annual GVN Short Course is a unique opportunity I wish I had when I was new to the field,” said Gallo, who is also The Homer and Martha Gudelsky Distinguished Professor in Medicine, Co-Founder & Director, Institute of Human Virology (IHV), University of Maryland School of Medicine, a GVN Center of Excellence. “Scientific research challenges, such as developing an effective preventive HIV vaccine candidate, abound. It is incumbent upon my colleagues and I to cultivate an environment to advance and train burgeoning medical virologists, and to prepare them to take collective responsibility for current and future viral threats.”

“This year’s agenda included presentations from GVN experts in hepatitis, hepatocellular carcinoma, human T-cell leukemia virus, human immunodeficiency virus, measles, arboviruses, Ebola, Lassa fever, bioinformatics, influenza, human papilloma viruses, polio and other enteroviruses, bio-surveillance, biosafety and biosecurity, antiviral drug discovery, laboratory diagnostics, vaccine development and One Health,” said Bréchot. “Participants visited GVN Centers of Excellence at the IHV and the Johns Hopkins Bloomberg School of Public Health, where they received an insectary tour. They also visited the National Institutes of Health for a tour of the National Library of Medicine and to hear presentations from the National Institute of Allergy and Infectious Diseases and the Fogarty International Research Center.”

At the end of the annual course, participants elect a fellow participant as the “next emerging leader in virology” based on leadership and expertise. This year’s nominee, who will return next year as a speaker, is Matilu Mwau, MB, ChB, MTM, DPhil, Chief Research Officer, Kenya Medical Research Institute. Past nominees include Florian Krammer, PhD (2014), Associate Professor, Department of Microbiology, Icahn School of Medicine at Mount Sinai, USA; Christina Gavegnano, PhD (2015), Assistant Professor, Department of Pediatrics, Emory University, USA; Miguel Garcia-Knight, PhD (2016), Centro de Investigaciones en Ciencias Microbiológicas, Benemérita Universidad Autónoma de Puebla, Mexico; Yuki Furuse, MD, PhD (2017), Assistant Professor at the Institute for Frontier Life and Medical Sciences at Kyoto University, Japan; and, Elysse Grossi-Soyster, MS, (2018) Laboratory Manager & Researcher, LaBeaud Lab, Stanford University School of Medicine.

“The GVN Annual Short Course is intense and comprehensive,” said Mwau. “We were trained by renowned experts including, Drs. Robert Gallo and Scott Weaver, on the most important emerging and reemerging viral diseases. By the end of the course, I had already decided that my infectious diseases research interests must be adjusted to capture these realities.”

“The GVN short course is a unique opportunity to learn first-hand from the experts who have generated much of the cutting edge research that forms the basis of our understanding of viral outbreaks causing the worst diseases in the world today,” said Allison Totura, PhD, a participant of this year’s course and ORISE Postdoctoral Research Fellow, Viral Pathogenesis Branch, Virology Division, U.S. Army Medical Research Institute of Infectious Diseases. “To be able to gain the perspective of collective leaders in the many aspects of medical virology on where the field stands as well as where it is going is an unparalleled resource to early career scientists. Although I have a PhD in Microbiology and Immunology, this course helped to fill gaps in my didactic training that can only be provided by the best of the best in the fields of basic and translational science. One of the greatest benefits of the course is the connections made with virologists studying similar pathogens, as the GVN works to link virologists around the globe who have similar interests, but might not otherwise connect with each other.”*

This year’s GVN Short Course speakers, in addition to Gallo and Bréchot, among others, included: Konstantin Chumakov, PhD, Associate Director for Research, Office of Vaccines Research and Review, U.S. Federal Drug Administration; José Esparza MD, PhD, Adjunct Professor of Medicine, IHV and formerly of the Bill & Melinda Gates Foundation and the World Health Organization; Genoveffa Franchini, MD, Senior Investigator, Vaccine Branch, Head, Animal Models and Retroviral Vaccines Section, National Cancer Institute, NIH; Robert Garry, PhD, Professor of Microbiology and Immunology, Associate Dean for the Graduate Program in Biomedical Sciences, Tulane Medical School; Diane Griffin MD, PhD, University Distinguished Service Professor of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health; RADM Peter Kilmarx, MD, FACP, FIDSA, Deputy Director, Fogarty International Center, National Institutes of Health (NIH); Shyam Kottilil, MD, PhD, Professor of Medicine, Director, Division of Clinical Care and Research, IHV; Christopher Kratochvil, MD, Professor, Associate Vice Chancellor for Clinical Research Chief Medical Officer, UNeHealth, University of Nebraska Medical Center; Mary Marovich, MD, Director, Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH; Gene Morse, PharmD, FCCP, BCPS, SUNY Distinguished Professor, School of Pharmacy and Pharmaceutical Sciences, Director of the UB Center for Integrated Global Biomedical Sciences, Co-Director of the SUNY Global Health Institute, University at Buffalo; Ab Osterhaus, PhD, DVM, Director, Research Center for Emerging Infections and Zoonoses, Professor, University of Veterinary Medicine Hannover, CEO, Artemis One Health Foundation; Manizhe Payton, MPH, Director, Office of Clinical Site Oversight, Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH; Richard H. Scheuermann, PhD, Director, La Jolla Campus. J. Craig Venter Institute (JCVI); and, Scott Weaver, MS, PhD, John Sealy Distinguished University Chair in Human Infections and Immunity, John S. Dunn Distinguished Chair in Biodefense, Scientific Director, Galveston National Laboratory, The University of Texas Medical Branch.

The GVN is a global authority and resource for the identification and investigation, interpretation and explanation, control and suppression, of viral diseases posing threats to mankind. It enhances the international capacity for reactive, proactive and interactive activities that address mankind-threatening viruses and addresses a global need for coordinated virology training through scholarly exchange programs for recruiting and training young scientists in human and animal virology. The GVN also serves as a resource to governments and international organizations seeking advice about viral disease threats, prevention or response strategies, and GVN advocates for research and training on virus infections and their many disease manifestations.

The GVN will host its 12th International meeting in Colombia, Medellin, September 13-15, 2020.

*The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

About the Global Virus Network (GVN)

The Global Virus Network (GVN) is a non-profit, 501(c)(3) organization, comprised of leading human and animal virologists from 30 countries. The GVN’s mission is to combat current and emerging pandemic viral threats through international collaborative research, training the next generation of medical virologists, and advocacy. For more information, please visit www.gvn.org. Follow us on Twitter @GlobalVirusNews

Media Contact:
Nora Samaranayake, GVN
410-706-8614
nsamaranayake@gvn.org

A Summary of Recent Advances in Ebola Treatment

August 21, 2019

Only two years ago, neither a vaccine cure for the Ebola Virus, nor effective antivirals existed to prevent Ebola Virus Disease. Recovery for those infected was through the strength of their own immune system, and according to the U.S. Centers of Disease Control and Prevention (CDC), doctors treated patients while keeping them well hydrated, and providing supportive care, helping them to breathe to boost the immune system which offered a better chance to fight off the disease. Doctors attempted to give the patients blood serum transfusions from the antibodies of those who survived Ebola. The current wave, 2018-2019, in the Democratic Republic of the Congo (DRC), is the second deadliest ever. Untreated patients have a 70% death-rate; while, vaccinated persons have a 90% survival rate. Last summer, 1,800 people perished in the DRC (World Health Organization and BBC News, August 13, 2019).

Today, two new antibody-based therapies, REGN-EB3, led by Neil Stahl, PhD, Executive Vice President of Research and Development at Regeneron Pharmaceuticals, and mAB114, under the direction of Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases (NIAID), were recently discovered most effective against the Ebola outbreak in the DRC, based on synthetic, monoclonal antibodies and interruption of the virus life-cycle. Previously, drug treatment, ZMAPP/MAPP of Biopharmaceuticals carried a 49% fatality rate, and Remdesivir from Gilead has a 53% fatality rate. Of the four new treatments, in November 2018, randomized trials in four towns, REGN-EB3 and mAB-114 proved most effective. Regeneron’s REGN-EB3 is most recommended with 29% fatality rate reduction; followed by NIAID’s mAB114 at a 34% rate reduction, (BBC News, August 13, 2019). When treated early, the mortality drops to 6%, and 11%, respectively.

Treatment challenges exist, as refrigeration of RGN-EB3 and AB-114 make distribution difficult. Small molecule antivirals serve better in urban and remote areas, not requiring refrigeration, and thus, complementing antibody-based therapies. The virus, moreover, may mutate, becoming antibody resistant; therefore, options are needed.

Meanwhile, Merck vaccine candidate, rVSV-ZEEBOV, showed 100% protection rate, during a Phase 3, single-dose, cluster, randomized, ring trial in Guinea; where 5,837 subjects given the shot were not infected ten days after immunization. V920 (rVSV-ZEBOV-GP) is a recombinant, replication-competent Ebola vaccine, consisting of a vesicular stomatitis which has been genetically engineered to express a glycoprotein from the Zaire strain, provoking a naturalized immune response. The trial was conducted by a team of researchers from the WHO, the Norwegian Institute of Public Health, the Health Ministry of Guinea and Médecins Sans Frontières, among others. “We believe the world is on the verge of an efficacious Ebola vaccine,” said Marie-Paule Kieny, the Word Health Organization’s assistant director-general for health systems and innovation (Precision vaccinations, Carlson, Robert & EPG Health, August 2, 2017). Marie-Paule Kieny and Anne Marie Henao Restrepo, et al., performed the first successful Phase 1 and 2 Ebola vaccine clinical trial, March 23, 2016-January 20, 2017, (Lancet, February 04, 2017).

Merck’s clinical trials are in their final stages, and are expected completion by the end of 2020. The vaccine is designed for post-exposure settings, including high fatality adult, maternal and neonatal groups. Screening, population mapping and a ring strategy is performed, identifying high-risk areas. Ebola treatment centers provide, in addition, aggressive rehydration, correction of electrolyte imbalances and nutritional support. This supportive care is a prerequisite to the use of novel therapeutics or vaccines.

Drugs alone will not solve the problem, however, community-foreign preparedness, regional capacity-building, vaccine prevention, surveillance and therapeutic treatment will all be required. The disease is exacerbated, and may continue to spread. Furthermore, due to government instability, war and genocide, lack of education, infrastructure, and cultural beliefs fostering mistrust in vaccines, healthcare workers and a general lack of preparedness, treatment, community engagement and trust building will be essential to effective care provision (New England Journal of Medicine, August 25, 2018).

 

About the Global Virus Network (GVN)

The Global Virus Network (GVN) is a non-profit, 501(c)(3) organization, comprised of leading human and animal virologists from 29 countries. The GVN’s mission is to combat current and emerging pandemic viral threats through international collaborative research, training the next generation of medical virologists, and advocacy. For more information, please visit www.gvn.org. Follow us on Twitter @GlobalVirusNews

Ebola Outbreak in the Democratic Republic of the Congo Shines Light on Global Challenges

Last Week the WHO Declared the Epidemic a Public-Health Emergency of International Concern

Baltimore, MD, USA, July 24, 2019: Last week, the World Health Organization (WHO) declared the current Ebola outbreak in the Democratic Republic of the Congo (DRC) a public-health emergency of international concern (PHEIC), signaling a risk to multiple countries that requires a coordinated international response. Worse than the previous nine Ebola outbreaks in the DRC combined, more than 2,500 people are listed as confirmed or probable cases and at least 1,700 have died. This is only the fifth PHEIC declared following similar alarms for the H1N1 influenza pandemic (2009), a major outbreak of wild polio (2014), the West African Ebola epidemic (2013-16) and the Zika epidemic (2015-16). Each of these public health emergencies have highlighted weaknesses in our response systems, exposing the urgent need for improved infrastructure, scientific knowledge, and diagnostic technologies in areas most at risk.

“The Global Virus Network and all the scientists collaborating with the network will strongly support efforts of WHO following up on the PHEIC declaration for the current Kivu Ebola epidemic” said Prof. Christian Bréchot, MD, PhD, president of the Global Virus Network (GVN), professor at the University of South Florida and executive director of the Romark Company Institute for Medical Research.

The declaration of the PHEIC was triggered when a case of Ebola was diagnosed in Goma, the capital of North Kivu province in the eastern Democratic Republic of the Congo, with greater than 1 million people that directly borders Rwanda and has an international airport. Previously, two children and their grandmother carried the virus into Uganda, while all three died. Uganda, where no more Ebola cases have occurred, is the site of a GVN center and has a strong track record of controlling Ebola.

Prof. Pontiano Kaleebu, PhD, MB ChB, director of the Uganda Virus Research Institute (UVRI), director, Center of Excellence, GVN and director of the Medical Research Council/ Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit said, “Uganda has a strong surveillance network and fortunately has been able to limit this Ebola outbreak as well as outbreaks over the past decade to only a few cases.”

The current outbreak was declared in August 2018, but the Ebola virus was likely already spreading in eastern DRC for many months. Bringing the outbreak under control has proven to be challenging. While more than 70 million people are controlled and more than 160,000 vaccines have been administered, the outbreak continues The eastern provinces of North Kivu and Ituri border Rwanda and Uganda, and are active conflict zones where there have been over 70 attacks on Ebola clinics or health workers since January.  There are many new confirmed cases that are unable to be traced to an existing Ebola contact. Therefore, it is likely that there are many deaths that have occurred that have gone unrecorded.

Despite the security challenges of the current epidemic, research on four therapies for Ebola is ongoing. This proves that research on cures and prevention of Ebola can, and should, occur under even the most dire outbreak conditions.

“The 2014-2015 Ebola outbreak drove an impressive advancement of knowledge,” said Prof. Giuseppe Ippolito, MD, MSc (HCMO), FRCPE, the scientific director of the National Institute for Infectious Diseases (INMI) “Lazzaro Spallanzani” in Rome, director, Center of Excellence, Global Virus Network and director of the World Health Organization (WHO) Collaborating Center for clinical care, diagnosis, response and training on Highly Infectious Diseases at INMI. “Preparedness and response must now be driven by scientific results and available evidence, involving more international and national public health institutions to alleviate the burden for humanitarian NGOs that so far stand alone. Investing in the training of a new generation of experts in virology and clinical epidemiology is critical to addressing emerging infections.”

The current Ebola outbreak in Congo has not yet achieved the magnitude of the West African epidemic. The West African Ebola epidemic, which infected at least 28,000 people and killed over 11,000, is again in the news this week with the release of a new book, Crisis in the Red Zone, a sequel to The Hot Zone by Richard Preston. The Hot Zone, published twenty-five years ago, documented events in which monkeys at a primate holding facility in Reston Virginia, only 20 miles from the center of Washington DC, developed a fatal illness. As the disease caused by Reston virus, a close relative of the Ebola virus, spread through the monkeys at the facility, the help of scientists at the nearby United States Army Medical Research Institute for Infectious Diseases (USAMRIID) at Fort Detrick Maryland was enlisted.

This time Preston puts much more focus on African healthcare workers and scientists. Crisis in the Red Zone describes the early events of the Ebola outbreak as the virus spread from Guinea to the Kenema Government Hospital where Dr. Sheik Humarr Khan and his team attempted to manage the influx of Ebola cases. Doctors and nurses such as Dr. Khan, head nurse and midwife Mbalu Fonnie, and nurses Alex Moigboi, Alice Kovoma and Nancy Yoko, who paid the ultimate price, are fittingly portrayed as heroes. Kenema Government Hospital has been closely affiliated with the Tulane University GVN Center of Excellence for nearly 15 years, working on Lassa fever, a disease that has many similarities to Ebola.

Prof. Robert F. Garry, Jr., PhD, professor of microbiology and immunology, Tulane University and director, Center of Excellence, GVN., commented that, “Crisis in the Red Zone provides a detailed accounting of the challenges my Sierra Leonean colleagues faced in the early days of the West African Ebola outbreak, while they awaited needed assistance from the international community. Unfortunately, some believed that the outbreak in Sierra Leone would burn out in a few weeks delaying a full scale intervention by the United States, WHO and others. New approaches to outbreak responses based on local preparedness, like those lead by GVN, are urgently needed.”

The current Ebola outbreak in the eastern DRC and the West African Ebola outbreak are but two examples of inadequate approaches to disease outbreaks that rely on an influx of foreign responders and have repeatedly been delayed and under-resourced. GVN is founded on the principle that preparedness for emerging viral diseases will necessitate deeply rooted collaborative research between local and global partners, and transformation of diagnostic tools and regional surveillance networks.

“The world is still vulnerable and under-prepared,” said Prof. Robert C. Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor in Medicine, co-founder and director, Institute of Human Virology, University of Maryland School of Medicine and co-founder and international scientific advisor, Global Virus Network. “There is an urgent, unmet need for new proactive measures that are locally established, community-based and rooted in symmetrical partnerships to address the challenges that viruses, including those that are as yet unknown, pose to global health and security.”

GVN represents 48 Centers of Excellence and 7 affiliates in 29 countries and comprises foremost experts in every class of virus causing disease in humans. It is a global authority and resource for the identification and investigation, interpretation and explanation, control and suppression, of viral diseases posing threats to mankind. It enhances the international capacity for reactive, proactive and interactive activities that address mankind-threatening viruses and addresses a global need for coordinated virology training through scholarly exchange programs for recruiting and training young scientists in medical virology. The GVN also serves as a resource to governments and international organizations seeking advice about viral disease threats, prevention or response strategies, and GVN advocates for research and training on virus infections and their many disease manifestations.

 

Read More: Ebola Virus Q&A

 

About the Global Virus Network (GVN)

The Global Virus Network (GVN) is essential and critical in the preparedness, defense and first research response to emerging, exiting and unidentified viruses that pose a clear and present threat to public health, working in close coordination with established national and international institutions. It is a coalition comprised of eminent human and animal virologists from 48 Centers of Excellence and seven Affiliates in 29 countries worldwide, working collaboratively to train the next generation, advance knowledge about how to identify and diagnose pandemic viruses, mitigate and control how such viruses spread and make us sick, as well as develop drugs, vaccines and treatments to combat them. No single institution in the world has expertise in all viral areas other than the GVN, which brings together the finest medical virologists to leverage their individual expertise and coalesce global teams of specialists on the scientific challenges, issues and problems posed by pandemic viruses. The GVN is a non-profit 501(c)(3) organization. For more information, please visit www.gvn.org. Follow us on Twitter @GlobalVirusNews

Media Contact:

Nora Samaranayake, GVN

410-706-8614

nsamaranayake@gvn.org

The Global Virus Network (GVN) Announces The Addition Of Three New Centers Of Excellence Joining Organization

University of Wisconsin-Madison Global Health Institute, U.S. Food and Drug Administration’s Office of Vaccine Research and Review and the Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation Join Renowned Global Virus Network to Combat Viral Diseases

Baltimore, Maryland, USA, June 4, 2019: The Global Virus Network (GVN), representing 48 Centers of Excellence and 7 Affiliates in 29 countries comprising foremost experts in every class of virus causing disease in humans, announced today the addition of the University of Wisconsin-Madison (UW-Madison) Global Health Institute, the U.S. Food and Drug Administration’s Office of Vaccine Research and Review (FDA-OVRR) and the Russian Federation’s Smorodintsev Research Institute of Influenza (the Institute) as its newest Centers of Excellence.  The announcement was made by Robert Gallo, MD, GVN co-founder and international scientific advisor and Christian Bréchot, MD, PhD, GVN president.

“The addition of these three Centers deepen our viral expertise in basic science, zoonotic and vaccine and drug therapy expertise, among other advantages,” said Dr. Gallo, The Homer & Martha Gudelsky Distinguished Professor in Medicine and Director of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine, a GVN Center of Excellence. “UW-Madison is an impressive institution with a number of top virologists who will contribute to the GVN’s overall research and translational programs and global reach.  The FDA-OVRR will enhance the GVN’s contributions in the development of viral vaccines and drug therapeutics, while the Smorodintsev Research Institute of Influenza will contribute to our current influenza studies and other acute respiratory viral infection research.”

“The addition of two superb U.S. institutions and an accomplished Russian institution is a tribute to our commitment to advance science regardless of governments politics,” said Dr. Bréchot, professor at the University of South Florida and executive director of the Romark Company Institute for Medical Research. “With these new additions, the GVN will strengthen its biosecurity initiatives including our recently established Anticipation & Preparedness Taskforce, among other important projects.”

The UW-Madison Global Health Institute Center of Excellence (UW-Madison) will be led by Tony Goldberg, PhD, DVM, MS, professor, department of pathobiological sciences, School of Veterinary Medicine, associate director for research, Global Health Institute, University of Wisconsin-Madison and Yoshihiro Kawaoka, DVM, MS, PhD, professor, department of pathobiological sciences, School of Veterinary Medicine, director, Influenza Research Institute, University of Wisconsin-Madison.  Virology research at UW-Madison includes studies of agents infecting humans, animals and plants, including highly pathogenic viruses (e.g. the ebolaviruses) and viruses with pandemic potential (e.g. influenza virus, Dengue virus, Zika virus). Virology research at UW-Madison is currently and historically strong with respect to viruses that cause human cancer and the biochemistry of host-virus interaction.

The new Centers’ activities range from basic research to the development of vaccines and therapeutics to public health and policy. UW-Madison has specific strengths in emerging viral pathogens and zoonoses, including rapid detection and characterization of novel viral agents, the development of animal models (especially primates) and the development of countermeasures such as vaccines and therapeutics.  The Center will work close with GVN Center of Excellence colleagues at the Colombia-Wisconsin One-Health Consortium (CWOHC), led by Jorge Osorio, DVM, PhD, professor, department of pathobiological sciences, School of Veterinary Medicine, University of Wisconsin-Madison.

“With our new GVN membership, and in partnership with Dr. Osorio, we will expand the range of global training opportunities for our graduate students as well as provide the GVN with expertise in diverse viral systems of global importance and highly specialized methodologies,” said Drs. Goldberg and Kawaoka.  “We especially look forward to strengthening our international training opportunities via the GVN and forging new scientific collaborations with members of the GVN.”

The FDA Office of Vaccines Research and Review (OVRR) GVN Center of Excellence is led by Konstantin Chumakov, PhD, associate director, OVRR, and is one of the three product offices, in addition to the Office of Blood Research and Review and the Office of Tissue and Advanced Therapies that regulates gene and cellular therapies. OVRR is in the FDA Center for Biologics Evaluation and Research (CBER), the world’s oldest institution responsible for regulation of biologically-derived medical products. CBER conducts regulatory research to better understand basic and translational aspects of regulated products and to inform development, evaluation and manufacture of various biologicals. The area of regulatory and research purview of OVRR includes vaccines against viral, bacterial and parasitic diseases, allergenic products for both diagnostic and therapeutic use, as well as live bio-therapeutic products, such as probiotics, fecal microbiota transplantation and phage therapy. The Office research portfolio includes 35 independent research programs covering a wide range of viral and bacterial pathogens.

“We are pleased to join the GVN in an official capacity, as we have participated in GVN activities since its inception,” said Dr. Chumakov.  “We will continue working with the GVN to facilitate the sharing of information to develop and evaluate effective vaccines.  We also look forward to participating in and supporting the training of the world’s next generation of virologists.”

The Smorodintsev Research Institute of Influenza Center of Excellence, led by Andrey Vasin, PhD its Director, Head of the Molecular Biology of Viruses Department, is a leading institute in the field of virology in Russia.  The Institute’s main activities are tightly interconnected with influenza and other respiratory viruses. The Institute is also an active part of the World Health Organization (WHO) Global Surveillance and Response System (GISRS) and is a WHO-recognized National Influenza Centre since 1971. Other activities include vaccine research and development projects, including the possibility to conduct pre-clinical and clinical trials (all phases), antiviral research and system biology approaches for investigation of host-pathogen interactions.

“The institute is already engaged in broad international collaborative research in the field of molecular virology, genetic engineering, improving the quality of diagnostic products, designing and producing new influenza vaccines and antiviral drugs,” said Dr. Vasin.  “The GVN provides a unique opportunity to collaborate in the areas of vaccine research and development against respiratory pathogens, including joint grant applications and experience exchange. We look forward to hosting clinical trials of vaccines and novel drugs according to International standards, in addition to training exchange programs for our young scientists.”

The GVN will co-host its 11th International Meeting with the Spanish Society of Virology in Barcelona, Spain from June 9-12, 2019. Top virologists from around the world will discuss topics, including immunology and vaccines, antiviral drug therapy, virus-host interaction, diagnostic virology and epidemiology, morphogenesis and structural biology, emerging and re-emerging viruses, viruses as biotechnological tools and trending topics in virology.

 

About the Global Virus Network (GVN)

The Global Virus Network (GVN) is essential and critical in the preparedness, defense and first research response to emerging, exiting and unidentified viruses that pose a clear and present threat to public health, working in close coordination with established national and international institutions. It is a coalition comprised of eminent human and animal virologists from 48 Centers of Excellence and seven Affiliates in 29 countries worldwide, working collaboratively to train the next generation, advance knowledge about how to identify and diagnose pandemic viruses, mitigate and control how such viruses spread and make us sick, as well as develop drugs, vaccines and treatments to combat them. No single institution in the world has expertise in all viral areas other than the GVN, which brings together the finest medical virologists to leverage their individual expertise and coalesce global teams of specialists on the scientific challenges, issues and problems posed by pandemic viruses. The GVN is a non-profit 501(c)(3) organization. Follow us on Twitter @GlobalVirusNews